Understanding LTBP4 in kidney fibrosis and cardiorenal syndrome
Molecular Mechanisms of Fibrillin/LTBP Superfamily in Renal Fibrosis and Cardiorenal
This study is trying to see how a protein called LTBP4 is linked to kidney damage in people with kidney fibrosis and heart-related kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT05012228 on ClinicalTrials.gov |
What this trial studies
This project aims to investigate the expression of LTBP4 in human renal fibrotic tissues. Investigators will collect residual renal tissues from patients with various causes of renal fibrosis and analyze the location and quantity of LTBP4 expression. The study seeks to establish a correlation between the severity of fibrosis and the expression levels of LTBP4 and other matrix proteins, providing insights into the molecular mechanisms involved in renal fibrosis and cardiorenal syndrome.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with abnormal kidney function, proteinuria, or hematuria.
Not a fit: Patients without any signs of kidney dysfunction or related symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and potential new targets for treating renal fibrosis and cardiorenal syndrome.
How similar studies have performed: While this study focuses on LTBP4, similar investigations into molecular mechanisms of fibrosis have shown promise in understanding renal conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Abnormal kidney function, proteinuria, hematuria Exclusion Criteria: * N/A
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Chi-Ting Su, MD, MPH, PhD
- Email: A01218@ntucc.gov.tw
- Phone: +88697262878
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.